Barclays Begins Coverage on Tvardi Therapeutics (NASDAQ:TVRD)

Stock analysts at Barclays initiated coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a research note issued to investors on Monday, MarketBeat reports. The firm set an “overweight” rating and a $61.00 price target on the stock.

A number of other analysts have also recently weighed in on the stock. Piper Sandler cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. BTIG Research lowered their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Saturday, September 27th. Finally, Raymond James Financial assumed coverage on shares of Tvardi Therapeutics in a research report on Monday, July 14th. They issued an “outperform” rating and a $62.00 price target on the stock. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $55.50.

Tvardi Therapeutics Trading Up 4.6%

NASDAQ TVRD opened at $7.00 on Monday. The company has a 50-day simple moving average of $31.25. Tvardi Therapeutics has a twelve month low of $5.65 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $43,000. Headlands Technologies LLC acquired a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $80,000. New York State Common Retirement Fund acquired a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $92,000. Finally, Bank of America Corp DE acquired a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $399,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.